Last reviewed · How we verify
Spinosad Topical — Competitive Intelligence Brief
marketed
Natural insecticide
Nicotinic acetylcholine receptors; GABA-gated chloride channels
Dermatology
Small molecule
Live · refreshed every 30 min
Target snapshot
Spinosad Topical (Spinosad Topical) — Cipher Pharmaceuticals Inc.. Spinosad is a natural insecticide that activates nicotinic acetylcholine receptors and GABA-gated chloride channels in insects, causing paralysis and death.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Spinosad Topical TARGET | Spinosad Topical | Cipher Pharmaceuticals Inc. | marketed | Natural insecticide | Nicotinic acetylcholine receptors; GABA-gated chloride channels |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Natural insecticide class)
- Cipher Pharmaceuticals Inc. · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Spinosad Topical CI watch — RSS
- Spinosad Topical CI watch — Atom
- Spinosad Topical CI watch — JSON
- Spinosad Topical alone — RSS
- Whole Natural insecticide class — RSS
Cite this brief
Drug Landscape (2026). Spinosad Topical — Competitive Intelligence Brief. https://druglandscape.com/ci/spinosad-topical. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing